Chronic Hepatitis

Top Story

FDA approves Epclusa for all HCV genotypes

FDA approves Epclusa for all HCV genotypes
June 28, 2016

Read the Perspective from Michael S. Saag, MD

The FDA announced it has approved Epclusa for the treatment of all chronic hepatitis C virus genotypes in adults with and without cirrhosis. For patients with moderate to severe cirrhosis, it is approved in combination with ribavirin.

Epclusa (sofosbuvir/velpatasvir, Gilead Sciences), a pangenotypic, once-daily tablet containing 400 mg of sofosbuvir and 100 mg of velpatasvir, is the first combination drug to treat all six major forms of HCV.

In the Journals

Insulin resistance associated with reduced protective anti-HBsA levels

June 27, 2016
Insulin resistance was positively associated with an increased reduction in protective anti-hepatitis B surface antigen levels in Korean men and women, according to…
Meeting News Coverage

Prednisolone increases infection in alcoholic hepatitis

June 24, 2016
Using prednisolone to treat elevating bacterial DNA in patients with alcoholic hepatitis increases the likelihood of developing infection within 7 days of treatment…
In the Journals

Low viremia, female sex associated with spontaneous HCV clearance

June 23, 2016
Recent data published in the Journal of Hepatology showed spontaneous clearance of hepatitis C virus infection is rare; however, it was more common in women and…
CME

Rapid Response from Barcelona: New Data in HCV Treatment

This activity is supported by an educational grant from AbbVie and Merck & Co., Inc.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
GI Bookshelf

Question 14: Why is Bloating Such a Problem in Patients With IBS?

From Curbside Consultation in IBS: 49 Clinical Questions
More »
Featured
Highlights from International Liver Congress

Highlights from International Liver Congress

Video
Meeting News Coverage

Sofosbuvir/ledipasvir regimen produced high SVR rates in patients with decompensated cirrhosis

November 14, 2014
More »
Breaking NewsPerspective

FDA approves Epclusa for all HCV genotypes

June 28, 2016
The FDA announced it has approved Epclusa for the treatment of all chronic hepatitis C virus genotypes in adults with and without cirrhosis. For…

In the Journals

Insulin resistance associated with reduced protective anti-HBsA levels

June 27, 2016
Insulin resistance was positively associated with an increased reduction in protective anti-hepatitis B surface antigen levels in Korean men and…

Meeting News Coverage

Prednisolone increases infection in alcoholic hepatitis

June 24, 2016
Using prednisolone to treat elevating bacterial DNA in patients with alcoholic hepatitis increases the likelihood of developing infection within 7…

In the Journals

Low viremia, female sex associated with spontaneous HCV clearance

June 23, 2016
Recent data published in the Journal of Hepatology showed spontaneous clearance of hepatitis C virus infection is rare; however, it was more common…

In the Journals

Baraclude therapy for HBV leads to lower than expected HCC incidence

June 22, 2016
Patients with hepatitis B virus infection treated with Baraclude had an unexpected lower incidence of hepatocellular carcinoma over time, although…

In the Journals

HBV/HIV coinfection leads to poorer outcomes in hospitalized patients

June 21, 2016
Recent findings published in the Journal of Viral Hepatitis showed that HBV/HIV coinfection led to poorer outcomes in hospitalized patients…

In the Journals

Maternal HBsAg comparable to viral load in predicting HBV in infants

June 21, 2016
Recent findings published in Hepatology showed that quantitative maternal hepatitis B surface antigen predicted chronic hepatitis B virus infection…

In the Journals

TDF therapy reduces incidence of mother-to-child HBV transmission

June 15, 2016
Mothers with high HBV DNA levels who received tenofovir disoproxil fumarate therapy late in pregnancy had reduced risk for perinatal mother-to-child…

Meeting News CoveragePerspective

HEPLISAV-B vaccine safe, effective against HBV in patients with type 2 diabetes

June 11, 2016
Adults with type 2 diabetes mellitus, who are more susceptible to hepatitis B virus infection than individuals without diabetes, had significantly…

In the Journals

PEG-IFN a-2b/entecavir does not boost virological response

June 10, 2016
Combining peginterferon alpha-2b with entecavir for patients with chronic hepatitis B virus did not improve virological response or hepatitis B…

More Headlines »
morganatic-roan morganatic-roan